Brandon Couillard: Adam, on the 10K Plex assay launched in the fourth quarter, can you just talk about level of customer interest in that rollout. How much of the current services business you expect to convert to the 10K assay? Or will there still be some customers that order the old assay and maybe the power on just the pricing premium that you might capture from that expanded content?
Adam Taich: Sure. Thanks, Brandon. As it relates to pricing, we’re in the process of working through that now. So we haven’t announced pricing commercially for 10K. So stay tuned on that one. As it relates to 10K, I mean, look, the proteome is vastly underutilized and it’s undermeasured, right? So similar to what we’ve all experienced in the genome, a full mapping of the proteome over time, we firmly believe is going to lead to substantial discoveries about mechanisms of action and various other insights around disease state. And by the time we get out there with 10K, our technology is going to measure half the human proteome in every sample, which is truly remarkable and market-leading. So we’re seeing incredible enthusiasm around it.
As it relates to who will stick sort of on the 7K, certainly, there are some studies that are out there where folks are maybe only halfway through kind of a cohort, and they’ve been running it on 7K. I can see in some of those folks sticking with 7K. And we are going to make that available for customers for a period of time until we sunset that. But I would expect that we’ll see most of our customers as we move into 2024 transition immediately to the 10K content.
Brandon Couillard: Okay. Got you. And then just in terms of your interim title and then Eliot coming on board with interim titles. Can you just kind of unpack why that’s still the case and maybe any update on, I guess, what seems to be still ongoing search process, maybe hadn’t just finalize it?
Adam Taich: Sure. Sure. Well, yes, we can parse the two roles. On the CEO side, I am maintaining the interim title for the time being. The company is not conducting a CEO search. And I’ve got to say the Board has been extremely supportive of me over the last couple of months. As it relates to — on the CFO side, we’ve really just been investing our time and effort getting Eliot up to speed. So it goes without saying we need absolutely excellent financial leadership. And really since the time that Eliot stepped in the door, we’ve really just been working to get him up to speed and ensuring that he’s got the resources to do a tremendous job for us, and we’ll keep you posted on that front as we move forward.
Operator: Thank you. That does conclude our Q&A for today. I’d like to turn the call back over to Adam Taich for any closing remarks.
Adam Taich: Well, first of all, I’d just like to thank everyone for joining us today and your ongoing interest in SomaLogic. We look forward to speaking to you next quarter. Thank you so much.
Operator: Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.
